You are here: Home » International » News » Companies
Business Standard

GSK, CureVac to develop Covid-19 vaccines aimed at new variants

Drugmaker GlaxoSmithKline said Wednesday it will work with a German biopharmaceutical company to develop new vaccines targeting emerging variants of COVID-19

Topics
Coronavirus Vaccine | GSK | Pharma sector

AP  |  London 

GSK, PHARMA, GLAXO

Drugmaker GlaxoSmithKline said Wednesday it will work with a German biopharmaceutical company to develop new vaccines targeting emerging variants of COVID-19 amid concerns that some mutations are making the virus harder to combat.

plans to invest 150 million euros (USD 181 million) to support the research of the Tubingen, Germany-based CureVac, which is developing vaccines that use messenger RNA to attack the disease. also said it will help make up to 100 million doses of the company's existing COVID-19 vaccine candidate this year.

The increase in emerging variants with the potential to reduce the efficacy of first generation COVID-19 vaccines requires acceleration of efforts to develop vaccines against new variants to keep one step ahead of the pandemic,'' the said in a statement.

The announcement comes as public health officials around the world raise concerns about new virus variants that are more contagious or resistant to existing vaccines.

While viruses mutate constantly, most of the changes cause little concern. But scientists are closely tracking these mutations to make sure they quickly identify variants of concern.

Authorities in England this week are conducting house to-house coronavirus testing in targeted communities in a bid to snuff out a new variant before it spreads widely and undermines a nationwide vaccination program.

British authorities want to test about 80,000 people in eight areas where the variant, first identified in South Africa, is believed to be spreading after a handful of cases were found in people who had no contact with the country or anyone who traveled there.

Public health officials are concerned about the variant first identified in South Africa because it contains a mutation of the virus' characteristic spike protein targeted by existing vaccines. The mutation may mean the vaccines offer less protection against the variant.

We believe that next generation vaccines will be crucial in the continued fight against COVID-19,'' Chief Executive Emma Walmsley said in the statement.

This new collaboration builds on our existing relationship with CureVac and means that together, we will combine our scientific expertise in mRNA and vaccine development to advance and accelerate the development of new COVID-19 vaccine candidates.''

In its full-year earnings published Wednesday, GSK said it expects further disruption for its vaccine business during the first half of the year given governments' prioritisation of COVID-19 vaccination programs and the resurgence in late 2020 of the pandemic.

It said this is expected to affect adult and adolescent immunizations, including Shingrix against shingles, notably in the U.S. Despite this, it expects a rebound in the second half of the year and that vaccine revenues in 2021 will be flat or grow slightly.

Overall, GSK saw sales in 2020 rise by 1 per cent to 34.1 billion pounds (USD 46 billion) and net profit increase 21 per cent to 6.4 billion pounds (USD 9.6 billion).

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, February 03 2021. 20:07 IST
RECOMMENDED FOR YOU
.